-
Can Noncalcified Plaques Contribute to Future Coronary Events?-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-29 Alastair J Moss,Michelle C Williams,David E Newby
-
Pulsed Field Ablation-Will Coronary Spasm Lead to Iconoclasm? JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-29 Bradley P Knight,Anna Pfenniger
-
Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-29 Chi Zhang,Petr Neuzil,Jan Petru,Moritoshi Funasako,Pavel Hala,Karel Kopriva,Jacob S Koruth,Srinivas R Dukkipati,Vivek Y Reddy
Importance In treating atrial fibrillation, pulsed field ablation (PFA) is a novel energy modality with comparable efficacy to conventional thermal ablation, such as radiofrequency ablation (RFA), but with the benefit of some preferentiality to myocardial tissue ablation. Studies have demonstrated important safety advantages, including the absence of esophageal injury or pulmonary vein stenosis and
-
Can Noncalcified Plaques Contribute to Future Coronary Events? JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-29 Muhammed I Erbay,Shriraj Susarla,Matthew J Budoff
-
High-Sensitivity Troponin in Pulmonary Embolism Risk Stratification-Proceed With Caution. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-22 Vinay Guduguntla,Robert O Bonow
-
High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-22 Behnood Bikdeli,Alfonso Muriel,Carmen Rodríguez,Sara González,Winnifer Briceño,Ghazaleh Mehdipoor,Gregory Piazza,Aitor Ballaz,Giuseppe Lippi,Roger D Yusen,Remedios Otero,David Jiménez
Importance High-sensitivity troponin tests can detect even milder cardiac troponin elevations in plasma, beyond the threshold of conventional troponin tests. Whether detection of low-grade cardiac troponin elevation is associated with outcomes of patients with hemodynamically stable pulmonary embolism (PE) and helps with risk stratification is unknown. Objective To determine the association between
-
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-22 Antonio Landi,Mirvat Alasnag,Dik Heg,Enrico Frigoli,Fazila Tun Nesa Malik,Ivan Gomez-Blazquez,Suzanne Pourbaix,Alaide Chieffo,Christian Spaulding,Fermin Sainz,Helen Routledge,Giuseppe Andò,Luca Testa,Alessandro Sciahbasi,Hussain Contractor,Nigel Jepson,Juan Mieres,Syed Saqib Imran,Husam Noor,Pieter C Smits,Marco Valgimigli,
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Objectives To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR. Design, Setting, and Patients This prespecified subgroup comparative
-
Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-15 Sanjiv J Shah,Nowell Fine,Pablo Garcia-Pavia,Allan L Klein,Fabio Fernandes,Neil J Weissman,Mathew S Maurer,Kurt Boman,Balarama Gundapaneni,Marla B Sultan,Perry Elliott
Importance Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized. Objective To examine the effect of tafamidis on cardiac function in patients with ATTR-CM. Design, Setting, and Participants This was an exploratory, post hoc analysis of the Tafamidis
-
Swollen Right Upper Limb in a Man in His 60s Undergoing Hemodialysis. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-15 Shengmei Liu,Sixian Hu,Liqing Peng
-
Irregular Rhythm in a Middle-Aged Man Presenting With New-Onset Heart Failure. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-15 Hussam Ali,Ilaria Passarelli,Riccardo Cappato
-
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-13 Selim R Krim,Senthil Anand,Stephen J Greene,Anqi Chen,Daniel Wojdyla,Juan Vilaro,Herbert Haught,John M Herre,Eric L Eisenstein,Kevin J Anstrom,Bertram Pitt,Eric J Velazquez,Robert J Mentz
Importance Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). Objectives To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF. Design, Setting, and Participants All patients with a documented ejection fraction
-
Neighborhood Environmental Burden and Cardiovascular Health in the US. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-13 Michael Liu,Vishal R Patel,Renee N Salas,Mary B Rice,Dhruv S Kazi,ZhaoNian Zheng,Rishi K Wadhera
Importance Cardiovascular disease is the leading cause of death in the US. However, little is known about the association between cumulative environmental burden and cardiovascular health across US neighborhoods. Objective To evaluate the association of neighborhood-level environmental burden with prevalence of cardiovascular risk factors and diseases, overall and by levels of social vulnerability
-
Prioritizing the Exposome to Reduce Cardiovascular Disease Burden. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-13 Erica S Spatz,Kai Chen,Harlan M Krumholz
-
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-12 Finnian R Mc Causland,Brian L Claggett,Muthiah Vaduganathan,Akshay Desai,Pardeep Jhund,Orly Vardeny,James C Fang,Rudolf A de Boer,Kieran F Docherty,Adrian F Hernandez,Silvio E Inzucchi,Mikhail N Kosiborod,Carolyn S P Lam,Felipe Martinez,Jose F Kerr Saraiva,Martina M McGrath,Sanjiv J Shah,Subodh Verma,Anna Maria Langkilde,Magnus Petersson,John J V McMurray,Scott D Solomon
Importance An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure. Objective To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or
-
Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-11 Jonathan W Cunningham,Pulkit Singh,Christopher Reeder,Brian Claggett,Pablo M Marti-Castellote,Emily S Lau,Shaan Khurshid,Puneet Batra,Steven A Lubitz,Mahnaz Maddah,Anthony Philippakis,Akshay S Desai,Patrick T Ellinor,Orly Vardeny,Scott D Solomon,Jennifer E Ho
Importance The gold standard for outcome adjudication in clinical trials is medical record review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication of medical records by natural language processing (NLP) may offer a more resource-efficient alternative but this approach has not been validated in a multicenter setting. Objective To externally
-
Innovation in Event Adjudication-Human vs Machine. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-11 Kenneth W Mahaffey,C Michael Gibson,Renato D Lopes
-
Mendelian Randomization and Cardiovascular Disease-Enabling Expert Readership. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-08 Pradeep Natarajan,Clyde W Yancy
-
Long-Term Clinical and Echocardiographic Outcomes Following the Ross Procedure: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-08 Maximiliaan L Notenboom,Giovanni Melina,Kevin M Veen,Fabio De Robertis,Giuditta Coppola,Paolo De Siena,Emiliano M Navarra,Jullien Gaer,Michael E K Ibrahim,Ismail El-Hamamsy,Johanna J M Takkenberg,Magdi H Yacoub
Importance The Ross procedure as treatment for adults with aortic valve disease (AVD) has been the subject of renewed interest. Objective To evaluate the long-term clinical and echocardiographic outcomes following the Ross procedure for the treatment of adults with AVD. Design, Setting, and Participants This post hoc analysis of a randomized clinical trial included adult patients (age <69 years) who
-
Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-08 June-Wha Rhee,Raju Pillai,Tianhui He,Alysia Bosworth,Sitong Chen,Liezl Atencio,Artem Oganesyan,Kelly Peng,Tati Guzman,Kara Lukas,Brianna Sigala,Aleksi Iukuridze,Lanie Lindenfeld,Faizi Jamal,Pradeep Natarajan,Scott Goldsmith,Amrita Krishnan,Michael Rosenzweig,F Lennie Wong,Stephen J Forman,Saro Armenian
Importance There is a paucity of information on the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular disease (CVD) in patients with cancer, including those with multiple myeloma (MM) undergoing hematopoietic cell transplant (HCT), a population at high risk of developing CVD after HCT. Objective To examine the association between CHIP and CVD in patients
-
The Longest Reported Outcomes of the Ross Procedure. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-08 Tsuyoshi Kaneko,Maral Ouzounian
-
Mendelian Randomization as a Tool for Cardiovascular Research: A Review. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-08 Michael G Levin,Stephen Burgess
Importance Mendelian randomization (MR) is a statistical approach that has become increasingly popular in the field of cardiovascular disease research. It offers a way to infer potentially causal relationships between risk factors and outcomes using observational data, which is particularly important in cases where randomized clinical trials are not feasible or ethical. With the growing availability
-
Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Johannes Burtscher,Martin Burtscher
-
Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Anthony J A Molina,Erich Gnaiger,Dalane W Kitzman
-
Educational Attainment and Lifetime Risk of Cardiovascular Disease. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Jared W Magnani,Hongyan Ning,John T Wilkins,Donald M Lloyd-Jones,Norrina B Allen
Importance Education is a social determinant of health. Quantifying its association with lifetime cardiovascular disease (CVD) risk has public health importance. Objective To calculate lifetime risk estimates of incident CVD and CVD subtypes and estimate years lived with and without CVD by education. Design, Setting, and Participants Included community-based cohort studies with adjudicated cardiovascular
-
Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Mohit K Turagam,Petr Neuzil,Boris Schmidt,Tobias Reichlin,Kars Neven,Andreas Metzner,Jim Hansen,Yuri Blaauw,Philippe Maury,Thomas Arentz,Philipp Sommer,Ante Anic,Frederic Anselme,Serge Boveda,Tom Deneke,Stephan Willems,Pepijn van der Voort,Roland Tilz,Moritoshi Funasako,Daniel Scherr,Reza Wakili,Daniel Steven,Josef Kautzner,Johan Vijgen,Pierre Jais,Jan Petru,Julian Chun,Laurent Roten,Anna Füting,Marc
Importance Previous studies evaluating the association of patient sex with clinical outcomes using conventional thermal ablative modalities for atrial fibrillation (AF) such as radiofrequency or cryoablation are controversial due to mixed results. Pulsed field ablation (PFA) is a novel AF ablation energy modality that has demonstrated preferential myocardial tissue ablation with a unique safety profile
-
Pulsed Field Closes Gender Gap in Atrial Fibrillation Ablation-Electrifying Insights. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Peter M Kistler,Louise Segan
-
Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Ahmed Sayed,Ann Marie Navar,Leandro Slipczuk,Christie M Ballantyne,Zainab Samad,Carl J Lavie,Salim S Virani
-
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Amber Sleem,Mark B Effron,Amanda Stebbins,Lisa M Wruck,Guillaume Marquis-Gravel,Daniel Muñoz,Richard N Re,Kamal Gupta,Carl J Pepine,Sandeep K Jain,Saket Girotra,Jeffrey Whittle,Catherine P Benziger,Peter M Farrehi,Kirk U Knowlton,Tamar S Polonsky,Matthew T Roe,Russell L Rothman,Robert A Harrington,W Schuyler Jones,Adrian F Hernandez
Importance Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations. Objective To assess whether receipt of enteric-coated vs uncoated aspirin is associated with effectiveness or safety outcomes. Design, Setting
-
Is There a Need for Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction? JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Sarah Godfrey,Ambarish Pandey,Haider J Warraich
-
Woman in Her 50s With an Intravenous Mass Extending to the Right Cardiac Chamber. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Jiehua Li,Quanming Li,Chang Shu
-
The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Jeremy William,David Chieng,Hariharan Sugumar,Liang-Han Ling,Louise Segan,Rose Crowley,Ahmed Al-Kaisey,Joshua Hawson,Sandeep Prabhu,Aleksandr Voskoboinik,Geoffrey Wong,Joseph B Morton,Geoffrey Lee,Alex J McLellan,Michael Wong,Rajeev K Pathak,Laurence Sterns,Matthew Ginks,Christopher M Reid,Prashanthan Sanders,Jonathan M Kalman,Peter M Kistler
Importance Catheter ablation for patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is associated with improved left ventricular ejection fraction (LVEF) and survival compared with medical therapy. Nonrandomized studies have reported improved success with posterior wall isolation (PWI). Objective To determine the impact of pulmonary vein isolation (PVI)
-
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Ankeet S Bhatt,Muthiah Vaduganathan,Brian L Claggett,Gregg C Fonarow,Milton Packer,Marc A Pfeffer,Sanjiv J Shah,Xian Shen,Joaquim Cristino,John J V McMurray,Scott D Solomon,Thomas A Gaziano
Importance The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those with below-normal EF. However, the upper bound of below normal is not clearly defined, and value determinations across a broader EF range are unknown
-
Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Laura P Cohen,Brandon K Bellows
-
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 John W Ostrominski,Suzanne V Arnold,Javed Butler,Gregg C Fonarow,Jamie S Hirsch,Swetha R Palli,Bonnie M K Donato,Christina M Parrinello,Thomas O'Connell,Eric B Collins,Jonathan J Woolley,Mikhail N Kosiborod,Muthiah Vaduganathan
Importance Individually, cardiac, renal, and metabolic (CRM) conditions are common and leading causes of death, disability, and health care-associated costs. However, the frequency with which CRM conditions coexist has not been comprehensively characterized to date. Objective To examine the prevalence and overlap of CRM conditions among US adults currently and over time. Design, Setting, and Participants
-
Deep Learning for Cardiovascular Imaging: A Review. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Ramsey M Wehbe,Aggelos K Katsaggelos,Kristian J Hammond,Ha Hong,Faraz S Ahmad,David Ouyang,Sanjiv J Shah,Patrick M McCarthy,James D Thomas
Importance Artificial intelligence (AI), driven by advances in deep learning (DL), has the potential to reshape the field of cardiovascular imaging (CVI). While DL for CVI is still in its infancy, research is accelerating to aid in the acquisition, processing, and/or interpretation of CVI across various modalities, with several commercial products already in clinical use. It is imperative that cardiovascular
-
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Jean-Luc Balligand,Dulce Brito,Oana Brosteanu,Barbara Casadei,Christophe Depoix,Frank Edelmann,Vanessa Ferreira,Gerasimos Filippatos,Bernhard Gerber,Damien Gruson,Dirk Hasenclever,Kristian Hellenkamp,Ignatios Ikonomidis,Bartosz Krakowiak,Renaud Lhommel,Masliza Mahmod,Stefan Neubauer,Alexandre Persu,Stefan Piechnik,Burkert Pieske,Elisabeth Pieske-Kraigher,Fausto Pinto,Piotr Ponikowski,Michele Senni
Importance Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. Objective To determine whether activation
-
Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Jan-Quinten Mol,Rick H J A Volleberg,Anouar Belkacemi,Renicus S Hermanides,Martijn Meuwissen,Alexey V Protopopov,Peep Laanmets,Oleg V Krestyaninov,Robert Dennert,Rohit M Oemrawsingh,Jan-Peter van Kuijk,Karin Arkenbout,Dirk J van der Heijden,Saman Rasoul,Erik Lipsic,Laura Rodwell,Cyril Camaro,Peter Damman,Tomasz Roleder,Elvin Kedhi,Maarten A H van Leeuwen,Robert-Jan M van Geuns,Niels van Royen
Importance Even after fractional flow reserve (FFR)-guided complete revascularization, patients with myocardial infarction (MI) have high rates of recurrent major adverse cardiovascular events (MACE). These recurrences may be caused by FFR-negative high-risk nonculprit lesions. Objective To assess the association between optical coherence tomography (OCT)-identified high-risk plaques of FFR-negative
-
Long-Term Quality of Life After Out-of-Hospital Cardiac Arrest. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Harman Yonis,Kathrine Kold Sørensen,Henrik Bøggild,Kristian Bundgaard Ringgren,Carolina Malta Hansen,Christopher B Granger,Fredrik Folke,Helle Collatz Christensen,Britta Jensen,Mikkel Porsborg Andersen,Vicky L Joshi,Ann-Dorthe Zwisler,Christian Torp-Pedersen,Kristian Kragholm
Importance Allocating resources to increase survival after cardiac arrest requires survivors to have a good quality of life, but long-term data are lacking. Objective To determine the quality of life of survivors of out-of-hospital cardiac arrest from 2001 to 2019. Design, Setting, and Participants This survey study used the EuroQol Health Questionnaire, 12-Item Short Form Health Survey (SF-12), and
-
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 Christoffer Rasmus Vissing,Anna Axelsson Raja,Sharlene M Day,Mark W Russell,Kenneth Zahka,Harry M Lever,Alexandre C Pereira,Steven D Colan,Renee Margossian,Anne M Murphy,Charles Canter,Richard G Bach,Matthew T Wheeler,Joseph W Rossano,Anjali T Owens,Lee Benson,Luisa Mestroni,Matthew R G Taylor,Amit R Patel,Ivan Wilmot,Philip Thrush,Jonathan H Soslow,Jason R Becker,Christine E Seidman,Neal K Lakdawala
Importance Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. Objective To explore the potential for valsartan to modify disease development, and to characterize short-term
-
Medical Editors vs Nuclear Weapons-Is the Pen Mightier Than the Sword? JAMA Cardiol. (IF 24.0) Pub Date : 2023-11-01 James E Muller,Joseph Gold Hodgkin
-
Regulatory Oversight of Cardiovascular Devices-Why We Care. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Clyde W Yancy,Patrick T O'Gara,Robert O Bonow
-
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Divaka Perera,Matthew Ryan,Holly P Morgan,John P Greenwood,Mark C Petrie,Matthew Dodd,Roshan Weerackody,Peter D O'Kane,Pier Giorgio Masci,Muhummad Sohaib Nazir,Alexandros Papachristidis,Navtej Chahal,Rajdeep Khattar,Saad M Ezad,Stam Kapetanakis,Lana J Dixon,Kalpa De Silva,Adam K McDiarmid,Michael S Marber,Theresa McDonagh,Gerry P McCann,Tim C Clayton,Roxy Senior,Amedeo Chiribiri,
Importance In the Revascularization for Ischemic Ventricular Dysfunction (REVIVED-BCIS2) trial, percutaneous coronary intervention (PCI) did not improve outcomes for patients with ischemic left ventricular dysfunction. Whether myocardial viability testing had prognostic utility for these patients or identified a subpopulation who may benefit from PCI remained unclear. Objective To determine the effect
-
Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Osman Moneer,Vinay K Rathi,James L Johnston,Joseph S Ross,Sanket S Dhruva
Importance The US Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) have different statutory authorities; FDA evaluates safety and effectiveness for market authorization of medical devices while CMS determines whether coverage is "reasonable and necessary" for its beneficiaries. CMS has recently enacted policies automatically providing supplemental reimbursement
-
Realigning Priorities in the Evaluation and Management of Patients With Heart Failure. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 James E Udelson,Gregg C Fonarow,Robert O Bonow
-
Assessment of Myocardial Viability in Ischemic Cardiomyopathy-Scarred by the Data but Still Alive. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Julio A Panza
-
Driving Medical Innovation-Focusing on the Evidence to Inform Best Care for Patients. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Lee A Fleisher
-
Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-25 Jacob B Pierce,Gregg C Fonarow,Stephen J Greene
-
Deep Learning to Identify Undiagnosed AF Using ECGs in Sinus Rhythm-Should We Rewire Our Models? JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-18 Mark S Brahier,Jonathan P Piccini
-
Lead Extraction and Mortality Among Patients With Cardiac Implanted Electronic Device Infection. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-18 Sean D Pokorney,Lindsay Zepel,Melissa A Greiner,Vance G Fowler,Eric Black-Maier,Robert K Lewis,Donald D Hegland,Christopher B Granger,Laurence M Epstein,Roger G Carrillo,Bruce L Wilkoff,Chantelle Hardy,Jonathan P Piccini
Importance Complete hardware removal is a class I recommendation for cardiovascular implantable electronic device (CIED) infection, but practice patterns and outcomes remain unknown. Objective To quantify the number of Medicare patients with CIED infections who underwent implantation from 2006 to 2019 and lead extraction from 2007 to 2019 to analyze the outcomes in these patients in a nationwide clinical
-
Explanation of Error in "Effect of Brief Counseling by Allied Health Professionals on Step Count of People With Peripheral Artery Disease: A Randomized Clinical Trial". JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-18 Jonathan Golledge,Alkira Venn,Joseph V Moxon
-
An Elderly Woman With Ventricular Tachycardia. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-18 Amr Idris,João L Cavalcante,David Lin
-
Deep Learning of Electrocardiograms in Sinus Rhythm From US Veterans to Predict Atrial Fibrillation. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-18 Neal Yuan,Grant Duffy,Sanket S Dhruva,Adam Oesterle,Cara N Pellegrini,John Theurer,Marzieh Vali,Paul A Heidenreich,Salomeh Keyhani,David Ouyang
Importance Early detection of atrial fibrillation (AF) may help prevent adverse cardiovascular events such as stroke. Deep learning applied to electrocardiograms (ECGs) has been successfully used for early identification of several cardiovascular diseases. Objective To determine whether deep learning models applied to outpatient ECGs in sinus rhythm can predict AF in a large and diverse patient population
-
Concordance of a High Lipoprotein(a) Concentration Among Relatives. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-11 Laurens F Reeskamp,Tycho R Tromp,Aniruddh P Patel,Shirin Ibrahim,Mark Trinder,Sara Haidermota,G Kees Hovingh,Erik S G Stroes,Pradeep Natarajan,Amit V Khera
Importance Lipoprotein(a) (Lp[a]) concentrations are a highly heritable and potential causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent consensus statements by the European Atherosclerosis Society and American Heart Association recommend screening of relatives of individuals with high Lp(a) concentrations, but the expected yield of this approach has not been quantified in
-
Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-11 Sofia Gonçalves Viamonte,Ana Vieira Joaquim,Alberto Jorge Alves,Eduardo Vilela,Andreia Capela,Cristina Ferreira,Barbara Fresco Duarte,Nuno Dias Rato,Madalena Pinheiro Teixeira,Aida Tavares,Mário Santos,Fernando Ribeiro
Importance Cardiovascular disease is a leading cause of morbidity in cancer survivors, which makes strategies aimed at mitigating cardiovascular risk a subject of major contemporary importance. Objective To assess whether a center-based cardiac rehabilitation (CBCR) framework compared with usual care encompassing community-based exercise training (CBET) is superior for cardiorespiratory fitness improvement
-
-
Linking Kidney Vessel Scarring to Cardiovascular Risk. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-01 Thibaut d'Izarny-Gargas,Alexandre Karras,Jean-Paul Duong-Van-Huyen
-
Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-01 Justin B Echouffo-Tcheugui,Sui Zhang,John W McEvoy,Stephen P Juraschek,Michael Fang,Chiadi E Ndumele,Robert H Christenson,Elizabeth Selvin
Importance It is unclear to what extent insulin resistance is associated with N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the general population after accounting for body composition. Objective To characterize the association of insulin resistance with NT-proBNP independently of measures of body composition in US adults. Design, Setting, and Participants In a cross-sectional design, data
-
Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-01 Leo Buckley,Ragnar Palsson,Sushrut S Waikar
-
Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events: A Systematic Review and Updated Meta-Regression Analysis. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-01 Iulia Iatan,Meijiao Guan,Karin H Humphries,Eunice Yeoh,G B John Mancini
Importance The association between changes in atherosclerotic plaque induced by lipid-lowering therapies (LLTs) and reduction in major adverse cardiovascular events (MACEs) remains controversial. Objective To evaluate the association between coronary plaque regression assessed by intravascular ultrasound (IVUS) and MACEs. Data Sources A comprehensive, systematic search of publications in PubMed, Embase
-
Erroneous Rapid Exchange Balloon Inflation During Coronary Angioplasty in a Male Patient in His 70s With Chronic Stable Angina. JAMA Cardiol. (IF 24.0) Pub Date : 2023-10-01 Shishir K Roul,Avinash Arke,Saurabh Ajit Deshpande